

Raised Over 13.5 Million for Pancreatic Cancer Research and Patient Support!



GRANTS AWARDED - UPDATES AND RESULTS

CancerSEEK - A Blood Test to Detect Pancreatic Cancer at Early Stages

It's the first and only FDA-approved multi-target stool DNA test for detecting colorectal cancer and pre-cancer covered by Medicare. To secure FDA approval, Exact Sciences will launch a registration trial for CancerSEEK designed to obtain sufficient data and results to support regulatory approval.

Investigator: Bert Vogelstein, MD, Johns Hopkins



Pancreatic Cancer Risk Assessment Tool Developed and Implemented

If it determines that someone has certain risk factors, they can be put in touch with genetic counselors and pancreatic cancer specialists at Perlmutter Cancer Center.

Investigator: Diane Simone, MD, NYU Lagone (visit find-pancancer-early.org to learn more)

The GENERATE (GENetic Education, Risk Assessment, and TEsting)

This study targeted people who had a relative with pancreatic cancer that may have been caused by an inherited change (mutation) in a gene. 1,000 participants were enrolled in this trial, which has recently been FDA-approved!

Investigators: Anirban Maitra, MBBS, Michael Goggins, MB, MD, Scott Lippman, MD, Sponsored by Dana Farber Institute

Developed a Personalized Pancreatic Cancer Screening Strategy

Implemented a strategy whereby GRS data is assessed in conjunction with testing for mutations in risk-associated HPGs for pancreatic cancer. In addition to family history, this is the most feasible way to identify a more substantial number of individuals who are at risk for developing pancreatic cancer.

Investigators: Jianfeng Xu, DrPH, Mark Talamonti, MD, Northshore Medical System Research Institute

Felix Project

Uses artificial intelligence (AI) to train computers to spot tumors in CT scans when the tumors are still small and localized. This effort is to use sophisticated computer programs that teach themselves to read CT scans the human eye cannot see.

Investigators: Elliot Fishman, MD, Bert Vogelstein, MD, Johns Hopkins



New Targets for Pancreatic Cancer Treatments Identified

A large international collaboration found new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumors' genes and proteins.

Investigator: Hui Zhag, PhD, MS, Johns Hopkins

Our Goal is to Live in a World Without Pancreatic Cancer!



GRANTS AWARDED - 2022 & 2023

Early and Effective – An Epigenetic Blood Test for Pancreatic Cancer

Utilizing 5hmC modification patterns in a liquid biopsy, this test will indicate the presence of a particular disease. This scientifically proves that these epigenetic markers can reliably predict pancreatic cancer at an early stage of disease. Currently seeking more samples to move to FDA stages.

Investigators: Chuan He, PhD, Marc Bissonette, MD, University of Chicago

The Study of High-Throughput Analysis of CDKN2A Variation

Focused on familial BRACA 2 genes for pancreatic cancer and melanoma. This study will use CDKN2A to develop a database system to assist in classifying these variants.

Investigator: Nicholas Roberts, MD, Johns Hopkins



At the Origin – BNIP3 and What it Tells us About Pancreatic Cancer Progression

Examines the BNIP3 gene and how it operates on a fundamental level to inform our understanding of how to diagnose pancreatic cancer earlier and more accurately.

Investigator: Kay Macleod, PhD, University of Chicago

Pancreatic Cancer Biomarkers

Developed a method to culture precancer lesions in three-dimensions, providing a critical system to study pancreatic precancers. Identifying precursor lesions before they become incurable invasive cancer is key to early detection.

Investigators: Ralph Hruban, MD, Laura Wood, MD, PhD, Johns Hopkins

CONTINUOUS PATIENT SUPPORT

Cancer Wellness Center

Psychosocial support and education for the pancreatic cancer community.

All services are provided by the Center's professional clinical staff, which is comprised of psychologists, counselors, and social workers.



Wellness House

Ongoing network support group for patients and families facing pancreatic cancer.

Kellogg Cancer Center

Located at the Highland Park Hospital Cancer Center, the team here provides financial support for nutrition and integrative medicine for pancreatic cancer patients.

Rolfe Pancreatic Cancer Foundation's mission is to provide personal support to those affected by pancreatic cancer through tailored resources, connections and education, and funding for early detection research.
To read more details about these updates visit rolfefoundation.org